Pomerantz Law Firm Alerts Sarepta Therapeutics Investors About Class Action Suit and Important Deadlines
On July 22, 2025, Pomerantz LLP announced the filing of a class action lawsuit against Sarepta Therapeutics, Inc. (NASDAQ: SRPT), focusing on potential securities fraud and unlawful business practices linked with the company. Investors who suffered losses due to their investment in Sarepta are urged to act quickly as crucial deadlines approach.
This lawsuit stems from several alarming disclosures made by Sarepta regarding the serious adverse effects of its drug, ELEVIDYS, which is intended for patients suffering from Duchenne muscular dystrophy. In a press release dated March 18, 2025, Sarepta revealed the tragic news of a patient dying from acute liver failure following treatment with ELEVIDYS. This disclosure led to a dramatic drop in Sarepta's stock price, plummeting by approximately 27% in a single day.
As the situation unfolded, the company's challenges continued. On April 4, 2025, Sarepta was compelled to suspend recruitment and dosing in multiple clinical studies after EU authorities requested a review of the events surrounding the March death. Following this revelation, shares of Sarepta fell another 7%, indicating growing concern among investors.
The downward spiral further intensified with another devastating report on June 15, 2025, when Sarepta disclosed a second death linked to treatment with ELEVIDYS. Consequently, they halted ongoing clinical trials and suspended distribution to non-ambulatory patients. This led to a staggering 42% decline in share price, with the stock closing around $20.94.
Adding to the turmoil, on June 24, 2025, the U.S. FDA issued a warning regarding the risks associated with ELEVIDYS, stating they were investigating the deaths attributed to the drug. This announcement caused another significant drop of 8.01% in the company's share price.
Given these alarming events, investors who purchased Sarepta securities during the Class Period are encouraged to reach out to Pomerantz LLP for participation in the class action. According to the notice, there is a deadline of August 25, 2025, for investors to apply for Lead Plaintiff status in the case if they wish to advocate for other affected shareholders.
The law firm of Pomerantz LLP, recognized as a leading entity in the realm of corporate and securities class action litigation, has a longstanding reputation for safeguarding the interests of investors impacted by corporate misconduct. The firm has a distinguished history of successfully obtaining multi-million dollar settlements on behalf of clients affected by securities fraud.
Those interested in joining the class action can obtain a copy of the complaint and further details from Pomerantz’s website. Inquiries can be directed to Danielle Peyton, who is managing communications about this case.
This situation highlights the critical importance of vigilance and prompt action among investors, as the landscape of securities litigation is both complex and ever-changing. In times like these, having a firm with a proven track record in class action litigation can make a significant difference for those seeking to reclaim their losses. Investors are encouraged to stay informed of any developments as the case progresses, as it may have far-reaching implications for Sarepta and its stakeholders.
This lawsuit stems from several alarming disclosures made by Sarepta regarding the serious adverse effects of its drug, ELEVIDYS, which is intended for patients suffering from Duchenne muscular dystrophy. In a press release dated March 18, 2025, Sarepta revealed the tragic news of a patient dying from acute liver failure following treatment with ELEVIDYS. This disclosure led to a dramatic drop in Sarepta's stock price, plummeting by approximately 27% in a single day.
As the situation unfolded, the company's challenges continued. On April 4, 2025, Sarepta was compelled to suspend recruitment and dosing in multiple clinical studies after EU authorities requested a review of the events surrounding the March death. Following this revelation, shares of Sarepta fell another 7%, indicating growing concern among investors.
The downward spiral further intensified with another devastating report on June 15, 2025, when Sarepta disclosed a second death linked to treatment with ELEVIDYS. Consequently, they halted ongoing clinical trials and suspended distribution to non-ambulatory patients. This led to a staggering 42% decline in share price, with the stock closing around $20.94.
Adding to the turmoil, on June 24, 2025, the U.S. FDA issued a warning regarding the risks associated with ELEVIDYS, stating they were investigating the deaths attributed to the drug. This announcement caused another significant drop of 8.01% in the company's share price.
Given these alarming events, investors who purchased Sarepta securities during the Class Period are encouraged to reach out to Pomerantz LLP for participation in the class action. According to the notice, there is a deadline of August 25, 2025, for investors to apply for Lead Plaintiff status in the case if they wish to advocate for other affected shareholders.
The law firm of Pomerantz LLP, recognized as a leading entity in the realm of corporate and securities class action litigation, has a longstanding reputation for safeguarding the interests of investors impacted by corporate misconduct. The firm has a distinguished history of successfully obtaining multi-million dollar settlements on behalf of clients affected by securities fraud.
Those interested in joining the class action can obtain a copy of the complaint and further details from Pomerantz’s website. Inquiries can be directed to Danielle Peyton, who is managing communications about this case.
This situation highlights the critical importance of vigilance and prompt action among investors, as the landscape of securities litigation is both complex and ever-changing. In times like these, having a firm with a proven track record in class action litigation can make a significant difference for those seeking to reclaim their losses. Investors are encouraged to stay informed of any developments as the case progresses, as it may have far-reaching implications for Sarepta and its stakeholders.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.